Nalmefene
Nalmefene structure
|
Common Name | Nalmefene | ||
|---|---|---|---|---|
| CAS Number | 55096-26-9 | Molecular Weight | 339.43 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H25NO3 | Melting Point | 188 - 190ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Purity | Quantity | Budget | Inquiry |
|---|
Use of NalmefeneNalmefene is a long acting opioid (MOR and DOR antagonist), and a partial KOR agonist. Nalmefene is used for opioid overdose and alcohol dependence[1]. |
| Name | (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol |
|---|---|
| Synonym | More Synonyms |
| Description | Nalmefene is a long acting opioid (MOR and DOR antagonist), and a partial KOR agonist. Nalmefene is used for opioid overdose and alcohol dependence[1]. |
|---|---|
| Related Catalog | |
| Target |
MOR, DOR, KOR[1] |
| References |
| Melting Point | 188 - 190ºC |
|---|---|
| Molecular Formula | C21H25NO3 |
| Molecular Weight | 339.43 |
| Exact Mass | 339.18300 |
| PSA | 52.93000 |
| LogP | 2.45040 |
| Storage condition | 2-8°C |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
|
~%
Nalmefene CAS#:55096-26-9 |
| Literature: Synthetic Communications, , vol. 22, # 16 p. 2313 - 2327 |
|
~%
Nalmefene CAS#:55096-26-9 |
| Literature: Journal of Medicinal Chemistry, , vol. 18, p. 259 - 262 |
![(4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-9-methoxy-7-methylene-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol structure](https://image.chemsrc.com/caspic/403/144265-45-2.png)
| Precursor 3 | |
|---|---|
| DownStream 0 | |
|
Treatment of alcohol dependence: recent progress and reduction of consumption.
Minerva Med. 105(6) , 447-66, (2014) Alcohol dependence (AD) is a major public health problem. Currently, three drugs for the treatment of AD have been approved by both the European Medicines Agency (EMA) and the Food and Drug Administra... |
|
|
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
JAMA 311(18) , 1889-900, (2014) Alcohol use disorders cause substantial morbidity and early mortality yet remain greatly undertreated. Medications are considerably underused.To conduct a systematic review and meta-analysis of the be... |
|
|
In vivo characterization of the opioid antagonist nalmefene in mice.
Life Sci. 86(15-16) , 624-30, (2010) The current study assessed the in vivo antagonist properties of nalmefene using procedures previously used to characterize the opioid antagonists naloxone, naltrexone, 6beta-naltrexol and nalbuphine.I... |
| Arthene |
| Nalmefenum |
| Nalmetrenum |
| Alcofene |
| Nalmetreno |
| 6-desoxy-6-methylenenaltrexone |
| Nalmetrene |
| Revex |
| nalmefene |
| Cervene |